💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Kamada Ltd. (KMDA)
« Back to company indexKMDA Chatter Timeline
Stock Ticker for KMDA
Most Active Tweeters for KMDA
| User | Tweets |
|---|---|
| @newsfilterio | 2 |
| @MarcJacksonLA | 2 |
| @sbwcws | 1 |
| @otcdynamics | 1 |
| @StockNewsNow | 1 |
Recent Tweets for KMDA
 |
@nk3901 @ZeContrarian7 any update on $kmda - I am long on this :) April 13th 2021, 2:04am |
 |
@moneymessage_ $KMDA $TAK - Kamada says amendment to Takeda deal could accelerate payments https://t.co/IrGenSCKnk April 8th 2021, 9:04am |
 |
@newsfilterio Kamada Announces Amendment to GLASSIA® License Agreement with Takeda $KMDA https://t.co/gMWntzdGpV April 8th 2021, 8:04am |
 |
@BeefEnt RT @StockNewsNow: $KMDA Kamada Announces Amendment to GLASSIA® License Agreement with Takeda https://t.co/TnJFes1N6J April 7th 2021, 9:04pm |
 |
@StockNewsNow $KMDA Kamada Announces Amendment to GLASSIA® License Agreement with Takeda https://t.co/TnJFes1N6J April 7th 2021, 8:04pm |
 |
@MarcJacksonLA $KMDA $TAK Kamada Announces Amendment to GLASSIA® License Agreement with Takeda https://t.co/iAen4e3qFg April 7th 2021, 8:04pm |
|
@newsfilterio Kamada says amendment to Takeda deal could accelerate payments $KMDA https://t.co/JP1f9O4y6h April 7th 2021, 8:04pm |
 |
@glitchbotio RT @MarketCurrents: $KMDA $TAK - Kamada says amendment to Takeda deal could accelerate payments https://t.co/qBMDtk1E8G April 7th 2021, 7:04pm |
 |
@MarketCurrents $KMDA $TAK - Kamada says amendment to Takeda deal could accelerate payments https://t.co/qBMDtk1E8G April 7th 2021, 7:04pm |
 |
@SmallCapsDaily $KMDA Kamada Announces Amendment to GLASSIA® License Agreement with Takeda GlobeNewswire https://t.co/6M23AJ3neN… https://t.co/A07LKD138R April 7th 2021, 3:04pm |
|
@MarcJacksonLA $KMDA Kamada Announces Amendment to GLASSIA® License Agreement with Takeda https://t.co/iAen4e3qFg April 7th 2021, 2:04pm |
 |
@NewsQuantified $KMDA Announces Amendment to GLASSIA® License Agreement with Takeda. Stock rockets +9.15% https://t.co/oaJsElQchk April 7th 2021, 12:04pm |
 |
@otcdynamics $KMDA Kamada Announces Amendment to GLASSIA® License Agreement with Takeda https://t.co/wyQn1kW2Cn April 7th 2021, 11:04am |
 |
@sbwcws Kamada announces amendment to GLASSIA license agreement with Takeda $KMDA $TAK April 7th 2021, 11:04am |
 |
@EdgarInsider FORM 6-K recently SEC filed. $KMDA #Kamada Ltd https://t.co/rLnpqlpKkY April 7th 2021, 11:04am |
 |
@bthefirsttoknow $KMDA.TA $KMDA Kamada Announces Amendment to GLASSIA License Agreement with Takeda https://t.co/2M57NVMIkA April 7th 2021, 11:04am |
 |
@stock_titan $KMDA Kamada Announces Amendment to GLASSIA® License Agreement with Takeda https://t.co/0sKICYz1wW April 7th 2021, 11:04am |
|
@StockNewsNow $KMDA Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globuli… https://t.co/5HGIC6Kgl8 March 31st 2021, 4:03pm |
|
@SmallCapsDaily $KMDA Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globuli… https://t.co/odnqDaRJp8 March 31st 2021, 4:03pm |
|
@MarcJacksonLA $KMDA Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globuli… https://t.co/txlVL6bVAy March 31st 2021, 2:03pm |
 |
@IOInvestors $KMDA +1.8% (reports Phase 1/2 anti-SARS-CoV-2 plasma-derived hyperimmune globulin treatment for COVID-19) https://t.co/9RdZ9bzCUp March 31st 2021, 1:03pm |
 |
@Gamma_Monkey Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 Trial $KMDA https://t.co/GmMNtF8I0o via @benzinga March 31st 2021, 12:03pm |
 |
@James__BondOO7 $KMDA results from a phase 1/2 study of its plasma-derived investigational treatment for COVID-19 has shown that t… https://t.co/gBVZpt39gn March 31st 2021, 12:03pm |
 |
@FearLessTraDeRx $KMDA Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globul… https://t.co/ZuqivTQMiz March 31st 2021, 10:03am |
|
@newsfilterio Kamada reports top-line results from mid-stage IgG trial in COVID-19 $KMDA https://t.co/mLODD8IMtn March 31st 2021, 10:03am |
 |
@Luckinvest17 $KMDA Kamada Announces Top-line Results From Phase 1/2 Clinical Trial Of Plasma-Derived Hyperimmune Globulin Treatment For COVID-19 March 31st 2021, 10:03am |
|
@EdgarInsider Filing for 6-K has been made with the SEC: $KMDA #Kamada Ltd https://t.co/l3Tn8IS7l5 March 31st 2021, 10:03am |
 |
@Beeken_health $KMDA - Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globu… https://t.co/kwefW270nE March 31st 2021, 10:03am |
 |
@StckPro $KMDA NEW ARTICLE : Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyper… https://t.co/9guYWSuOFN March 31st 2021, 10:03am |
|
@stock_titan $KMDA Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globuli… https://t.co/I9DYfBBZL4 March 31st 2021, 10:03am |
|
@MarcJacksonLA $KMDA Kamada to Present at the Jefferies Global Plasma Summit https://t.co/8db6TAGk8K March 9th 2021, 4:03pm |
|
@SmallCapsDaily $KMDA Kamada to Present at the Jefferies Global Plasma Summit GlobeNewswire https://t.co/l9UuEcgH7J #smallcapsdaily… https://t.co/Tie1BupuOn March 9th 2021, 4:03pm |
|
@StckPro $KMDA NEW ARTICLE : Kamada to Present at the Jefferies Global Plasma Summit https://t.co/2EH8hvRFJg Get all the lat… https://t.co/Ve909KpCOC March 9th 2021, 12:03pm |
|
@EdgarInsider Filing for 6-K has been made with the SEC: $KMDA #Kamada Ltd https://t.co/nohQJXhxm1 March 9th 2021, 12:03pm |
 |
@FlashAlert_me $KMDA [15s. delayed] filed form 6-K on March 09, 07:00:09 https://t.co/lofxps9jKP March 9th 2021, 12:03pm |
|
@StockNewsNow $KMDA Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and P… https://t.co/VCvs207e2L March 3rd 2021, 7:03pm |
|
@MarcJacksonLA $KMDA Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and P… https://t.co/ERQbxIhxaL March 3rd 2021, 4:03pm |
|
@SmallCapsDaily $KMDA Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and P… https://t.co/iprl7EAkMA March 3rd 2021, 4:03pm |
|
@otcdynamics $KMDA Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and P… https://t.co/HOjTD5WO7f March 3rd 2021, 12:03pm |
|
@sbwcws Kamada closes aquisition of FDA-licensed plasma collection center $KMDA March 3rd 2021, 12:03pm |
|
@StckPro $KMDA NEW ARTICLE : Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center fr… https://t.co/q6OnHC4Ts0 March 3rd 2021, 12:03pm |
|
@EdgarInsider SEC Form 6-K filed by $KMDA #Kamada Ltd https://t.co/ktmeSR5qcV March 3rd 2021, 12:03pm |
 |
@bthefirsttoknow $KMDA.TA $KMDA Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Bl… https://t.co/RfvGtD7K8U March 3rd 2021, 12:03pm |
|
@FlashAlert_me $KMDA [15s. delayed] filed form 6-K on March 03, 07:00:48 https://t.co/6FEpSTzCs5 March 3rd 2021, 12:03pm |
 |
@Peppons3 $KMDA Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and P… https://t.co/e3nRl4m17o March 3rd 2021, 12:03pm |
|
@StockNewsNow $KMDA Kamada Files Annual Report for the Year Ended December 31, 2020 https://t.co/gmU4kajv2c February 24th 2021, 9:02pm |
|
@SmallCapsDaily $KMDA Kamada Files Annual Report for the Year Ended December 31, 2020 GlobeNewswire https://t.co/mGTw1z8nQS… https://t.co/Z7hJvzHWeY February 24th 2021, 4:02pm |
|
@MarcJacksonLA $KMDA Kamada Files Annual Report for the Year Ended December 31, 2020 https://t.co/Rdu1DMQX7S February 24th 2021, 3:02pm |
|
@EdgarInsider A Form 6-K filing has been made with the SEC: $KMDA #Kamada Ltd https://t.co/rYdgOHt1cp February 24th 2021, 12:02pm |
 |
@ZeContrarian7 @Kodeshzuela Out of ALTG $KMDA holding took some profits $MDWD holding took some profits February 18th 2021, 9:02pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
